Theravance Biopharma Ebitda Over Time
| TBPH Stock | USD 9.61 0.36 3.61% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Theravance Biopharma Performance and Theravance Biopharma Correlation. Theravance |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.03) | Revenue Per Share 1.293 | Quarterly Revenue Growth 0.075 | Return On Assets (0.06) | Return On Equity (0.23) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Theravance Biopharma and related stocks such as Neoleukin Therapeutics, Instil Bio, and Achilles Therapeutics PLC Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TIL | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (33.4 M) | (152.8 M) | (217.4 M) | (146.1 M) | (153.4 M) |
| ACHL | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (33 M) | (57.8 M) | (78.4 M) | (70.4 M) | (74 M) |
| NXTC | (15 M) | (15 M) | (15 M) | (15 M) | (15 M) | (15 M) | (15 M) | (15 M) | (21.5 M) | (34.8 M) | (37.8 M) | (65 M) | (71.8 M) | (59 M) | (62 M) |
| ASMB | (7.2 M) | (33.7 M) | (24.8 M) | (19.4 M) | (23.9 M) | (29.6 M) | (44.1 M) | (51.4 M) | (92.1 M) | (102.2 M) | (64.8 M) | (91.9 M) | (93.6 M) | (64.2 M) | (67.4 M) |
| NUVB | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (43.4 M) | (89.3 M) | (119.5 M) | (99.6 M) | (104.6 M) |
| CTMX | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (29 M) | (32.4 M) | (55.5 M) | (44.6 M) | (76 M) | (108.3 M) | (78 M) | (81.1 M) | (98.9 M) | (4.3 M) | (4.5 M) |
| SNSE | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.4 M) | (18.5 M) | (36.8 M) | (48.8 M) | (33.4 M) | (35.1 M) |
| OVID | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (22.5 M) | (64.9 M) | (52.8 M) | (61.2 M) | (81.1 M) | 124.4 M | (54.2 M) | (58.7 M) | (61.6 M) |
| CNTB | (170.8 M) | (170.8 M) | (170.8 M) | (170.8 M) | (170.8 M) | (170.8 M) | (170.8 M) | (170.8 M) | (170.8 M) | (170.8 M) | (118.2 M) | (204.9 M) | (111.3 M) | (58.4 M) | (61.3 M) |
Theravance Biopharma and related stocks such as Neoleukin Therapeutics, Instil Bio, and Achilles Therapeutics PLC Ebitda description
My Equities
My Current Equities and Potential Positions
| Theravance Biopharma | TBPH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Cayman Islands |
| Exchange | NASDAQ Exchange |
USD 9.61
Check out Theravance Biopharma Performance and Theravance Biopharma Correlation. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Theravance Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.